Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Preclinical Characterization of the Anti-Leukemia Activity of the CD123 Antibody-Drug Conjugate, Pivekimab Sunirine (IMGN632)

Frances M. Cole, George S. Laszlo, Margaret C. Lunn-Halbert, Allie R. Kehret, Patrick A. Zweidler-McKay, Eduardo Rodríguez-Arbolí, David Wu, Kyle E. Nyberg, Junyang Li, Sheryl Y. T. Lim, Sribalaji Lakshmikanthan, Roland B. Walter

Blood (2024) 144 (Supplement 1): 2750.

https://doi.org/10.1182/blood-2024-200907

Published: 2024

Journal Articles

Targeting the Membrane-Proximal Domain of CD33 to Maximize the Efficacy of Natural Killer Cell-Based Immunotherapies

Sheryl Y. T. Lim, Frances M. Cole, George S. Laszlo, Margaret C. Lunn-Halbert, Jenny Huo, Junyang Li, Allie R. Kehret, Roland B. Walter

Blood (2024) 144 (Supplement 1): 3436.

https://doi.org/10.1182/blood-2024-198004

Published: 2024

Journal Articles

CD45-Directed Radioimmunotherapy with the Alpha-Emitter Astatine-211 As Conditioning for Autologous Hematopoietic Stem/Progenitor Cell Gene Therapy: Results from a Nonhuman Primate Model

Stefan Radtke, Kyle Swing, George S. Laszlo, Andrea Repele, Greta N. Kanestrom, Nicholas E Petty, Donald K. Hamlin, D. Scott Wilbur, Brenda M. Sandmaier, Hans-Peter Kiem, Roland B. Walter

Blood (2024) 144 (Supplement 1): 2014.

https://doi.org/10.1182/blood-2024-205992

Published: 2024

Journal Articles

Humanization of Clinically Used Murine CD45 Antibody for Optimized CD45-Targeted Radioimmunotherapy

George S. Laszlo, Brenda M. Sandmaier, David J. King, Allie R. Kehret, Kyle E. Nyberg, Jacob W. Barton, Frances M. Cole, Junyang Li, Margaret C. Lunn-Halbert, Donald K. Hamlin, D. Scott Wilbur, Johnnie J. Orozco, Shannon L. Dexter, Roland B. Walter

Blood (2024) 144 (Supplement 1): 4779.

https://doi.org/10.1182/blood-2024-201016

Published: 2024

Journal Articles

Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16/NKG2D Immune Modulating TriNKET ® BMS-986357 (CC-96191)

Margaret C. Lunn, George S. Laszlo, Sarah Eraiss, Mark T. Orr, Heidi K. Jessup, Henry Chan, Heather J. Thomas, Ann F. Cheung, Gregory P. Chang, Asya Grinberg, Eduardo Rodríguez-Arbolí, Sheryl Y. T. Lim, Allie R. Kehret, Jenny Huo, Frances M. Cole, Samuel C. Scharffenberger, Roland B. Walter

Blood (2023) 142 (Supplement 1): 1431.

https://doi.org/10.1182/blood-2023-185432

Published: 2023

Journal Articles

Optimizing Siglec-8-Directed Immunotherapy for Eosinophilic and Mast Cell Disorders

Jenny Huo, George S. Laszlo, Sheryl Y. T. Lim, Frances M. Cole, Allie R. Kehret, Junyang Li, Margaret C. Lunn, Jasmyn L. Persicke, Peter B. Rupert, Roland K. Strong, Roland B. Walter

Blood (2023) 142 (Supplement 1): 1781.

https://doi.org/10.1182/blood-2023-181476

Published: 2023

Journal Articles

Development of Astatine-211 ( 211 At)-Based Anti-CD123 Radioimmunotherapy for Acute Leukemias and Other CD123+ Hematologic Malignancies

George S. Laszlo, Johnnie J. Orozco, Allie R. Kehret, Margaret C. Lunn, Donald K. Hamlin, D. Scott Wilbur, Shannon L. Dexter, Melissa C. Comstock, Shyril O'Steen, Damian J. Green, Roland B. Walter

Blood (2021) 138 (Supplement 1): 3341.

https://doi.org/10.1182/blood-2021-152105

Published: 2021

Journal Articles

Targeting the Membrane-Proximal C2-Set Domain of CD33 for Improved CD33-Directed CAR T Cell Therapy

Salvatore Fiorenza, George S. Laszlo, Tinh-Doan Phi, Margaret C. Lunn, Delaney R. Kirchmeier, Colin D. Godwin, Erik L. Kimble, Cameron J. Turtle, Roland B. Walter

Blood (2021) 138 (Supplement 1): 2776.

https://doi.org/10.1182/blood-2021-149642

Published: 2021

Journal Articles

CRISPR/Cas9-Mediated Protection of Normal Hematopoiesis Combined with the CD33/CD3 Bispecific T-Cell Engager (BiTE) Antibody AMG330 for Improved AML Therapy

Olivier Humbert, PhD, Mallory J Llewellyn, George S. Laszlo, PhD, Roland B. Walter, MD PhD MS, Hans-Peter Kiem, MD PhD

Blood (2019) 134 (Supplement_1): 4427.

https://doi.org/10.1182/blood-2019-129399

Published: 2019

Journal Articles

Anti-Apoptotic BCL-2 Family Members Confer Resistance to Calicheamicin-Based Antibody-Drug Conjugate Therapy of Acute Leukemia

Colin D. Godwin, MDMPhil, Olivia M. Bates, BA, Sae Rin Jean, PhD, George S. Laszlo, PhD, Eliotte E. Garling, BA, Mary E. Beddoe, BS, Michael H. Cardone, PhD, Roland B. Walter, MD PhD MS

Blood (2019) 134 (Supplement_1): 2561.

https://doi.org/10.1182/blood-2019-126110

Published: 2019

Journal Articles

Engineering Resistance to CD33-Targeted Immunotherapy in Normal Hematopoiesis By CRISPR/Cas9-Deletion of CD33 Exon 2

Roland B. Walter, MD PhD MS, Olivier Humbert, PhD, George S. Laszlo, PhD, Sophie R. Sichel, BS, Christina M. Ironside, BS, Kevin G. Haworth, PhD, Olivia M. Bates, BA, Mary E. Beddoe, BS, Ray R. Carillo, BS, Hans-Peter Kiem, MD PhD

Blood (2018) 132 (Supplement 1): 2200.

https://doi.org/10.1182/blood-2018-99-117856

Published: 2018

Journal Articles

Bispecific Anti-CD123 x Anti-CD3 Adaptir™ Molecules APVO436 and APVO437 Have Broad Activity Against Primary Human AML Cells In Vitro

Colin D. Godwin, MD MPhil, Olivia M. Bates, BA, George S. Laszlo, PhD, Rebecca Gottschalk, Michael R. Comeau, Gabriela H. Hoyos, Roland B. Walter, MD PhD

Blood (2017) 130 (Supplement 1): 2639.

https://doi.org/10.1182/blood.V130.Suppl_1.2639.2639

Published: 2017

Journal Articles

High Expression of Myocyte Enhancer Factor 2C ( MEF2C ) Is Associated with Adverse Risk Features and Poor Outcome in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

George S. Laszlo, PhD, Todd A. Alonzo, PhD, Chelsea J. Gudgeon, BS, Kimberly H. Harrington, BS, Alex Kentsis, MD PhD, Robert B. Gerbing, MA, Yi-Cheng Wang, MS, Rhonda E. Ries, MA, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Alan S. Gamis, MD MPH, Soheil Meshinchi, MD PhD, Roland B. Walter, MD PhD MS

Blood (2015) 126 (23): 2570.

https://doi.org/10.1182/blood.V126.23.2570.2570

Published: 2015

Journal Articles

Multimerin-1 (MMRN1) As Novel Adverse Prognostic Marker in Acute Myeloid Leukemia: A Report from the Children’s Oncology Group

George S. Laszlo, PhD, Todd A. Alonzo, PhD, Chelsea J. Gudgeon, BS, Kimberly H. Harrington, BS, Robert B. Gerbing, MA, Yi-Cheng Wang, MS, Rhonda E. Ries, MA, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Alan S. Gamis, MD MPH, Soheil Meshinchi, MD PhD, Roland B. Walter, MD PhD MS

Blood (2014) 124 (21): 2330.

https://doi.org/10.1182/blood.V124.21.2330.2330

Published: 2014

Journal Articles

The Broad Activity of the CD33/CD3 Bispecific BiTE® Antibody AMG 330 in Primary Human AML Is Impacted By Disease Stage and Cytogenetic/Molecular Risk

Kimberly H. Harrington, BS, Chelsea J. Gudgeon, BS, George S. Laszlo, PhD, Kathryn J. Newhall, PhD, Angus M. Sinclair, PhD, Stanley R. Frankel, MD, Roman Kischel, MD, Guang Chen, PhD, Roland B. Walter, MD PhD MS

Blood (2014) 124 (21): 266.

https://doi.org/10.1182/blood.V124.21.266.266

Published: 2014

Journal Articles

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML

George S. Laszlo, Chelsea J. Gudgeon, Kimberly H. Harrington, Justine Dell’Aringa, Kathryn J. Newhall, Gary D. Means, Angus M. Sinclair, Roman Kischel, Stanley R. Frankel, Roland B. Walter

Blood (2014) 123 (4): 554–561.

https://doi.org/10.1182/blood-2013-09-527044

Published: 2014

Includes: Supplemental data

Journal Articles

Novel Long-Term Co-Culture Approach Identifies Prognostically Important Heterogeneity Of Stem/Progenitor Cell Involvement In Human Acute Myeloid Leukemia

George S. Laszlo, PhD, Jack M. Lionberger, MD, PhD, Kimberly H. Harrington, BS, Chelsea J. Gudgeon, BS, Megan Othus, PhD, Frederick R. Appelbaum, MD, Irwin D. Bernstein, MD, Roland B. Walter, MD, PhD

Blood (2013) 122 (21): 1318.

https://doi.org/10.1182/blood.V122.21.1318.1318

Published: 2013

NARROW

Preclinical Characterization of the Anti-Leukemia Activity of the CD123 Antibody-Drug Conjugate, Pivekimab Sunirine (IMGN632)

Targeting the Membrane-Proximal Domain of CD33 to Maximize the Efficacy of Natural Killer Cell-Based Immunotherapies

CD45-Directed Radioimmunotherapy with the Alpha-Emitter Astatine-211 As Conditioning for Autologous Hematopoietic Stem/Progenitor Cell Gene Therapy: Results from a Nonhuman Primate Model

Humanization of Clinically Used Murine CD45 Antibody for Optimized CD45-Targeted Radioimmunotherapy

Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16/NKG2D Immune Modulating TriNKET ® BMS-986357 (CC-96191)

Optimizing Siglec-8-Directed Immunotherapy for Eosinophilic and Mast Cell Disorders

Development of Astatine-211 ( 211 At)-Based Anti-CD123 Radioimmunotherapy for Acute Leukemias and Other CD123+ Hematologic Malignancies

Targeting the Membrane-Proximal C2-Set Domain of CD33 for Improved CD33-Directed CAR T Cell Therapy

CRISPR/Cas9-Mediated Protection of Normal Hematopoiesis Combined with the CD33/CD3 Bispecific T-Cell Engager (BiTE) Antibody AMG330 for Improved AML Therapy

Anti-Apoptotic BCL-2 Family Members Confer Resistance to Calicheamicin-Based Antibody-Drug Conjugate Therapy of Acute Leukemia

Engineering Resistance to CD33-Targeted Immunotherapy in Normal Hematopoiesis By CRISPR/Cas9-Deletion of CD33 Exon 2

Bispecific Anti-CD123 x Anti-CD3 Adaptir™ Molecules APVO436 and APVO437 Have Broad Activity Against Primary Human AML Cells In Vitro

High Expression of Myocyte Enhancer Factor 2C ( MEF2C ) Is Associated with Adverse Risk Features and Poor Outcome in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Multimerin-1 (MMRN1) As Novel Adverse Prognostic Marker in Acute Myeloid Leukemia: A Report from the Children’s Oncology Group

The Broad Activity of the CD33/CD3 Bispecific BiTE® Antibody AMG 330 in Primary Human AML Is Impacted By Disease Stage and Cytogenetic/Molecular Risk

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML

Novel Long-Term Co-Culture Approach Identifies Prognostically Important Heterogeneity Of Stem/Progenitor Cell Involvement In Human Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only